Top Markets
#1 Akedo Akedo +101.15%
#2 TENDIES TENDIES +83.99%
#3 Verus Coin Verus Coin +44.06%
#4 Threshold Network Threshold Network +41.14%
#5 Mubarak Mubarak +23.90%
#6 Bitway Bitway +19.06%
#7 Wrapped Aave Ethereum USDC Wrapped Aave Ethereum USDC +18.00%
#8 OSK OSK +16.18%
#9 MultiversX MultiversX +15.71%
#10 Kite Kite +15.59%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
Rank in Stocks #17592
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Share Price
$8.16
Last synced: 2025-06-26
Market Cap
$234.57M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Regulus Therapeutics Inc. (RGLS)

Category

Healthcare
P/S ratio for Regulus Therapeutics Inc. (RGLS)
P/S ratio as of September 2026 TTM: 0.00
According to Regulus Therapeutics Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.00. At the end of 2023 the company had a P/S ratio of 0.00.
P/S ratio history for Regulus Therapeutics Inc. from 2010 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 -100.00%
2020 4.72 109.88%
2019 2.25 -98.00%
2018 112.61 -92.50%
2017 1.50K 1,409.28%
2016 99.52 360.84%
2015 21.60 -76.58%
2014 92.22 534.60%
2013 14.53 256.69%
2012 4.07 5,109.59%
2011 0.08 -37.59%
2010 0.13 0.00%
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.95 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
12.19 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
24.99 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.75 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH